Efficacy of Larotrectinib (LOXO-101) in Adult and Pediatric TRK Fusion Cancers - 102164

Spotlight
Video

Efficacy of Larotrectinib (LOXO-101) in Adult and Pediatric TRK Fusion Cancers

Loading........
Description: David Michael Hyman, MD of Memorial Sloan-Kettering gives an overview his presentation, which focuses on the efficacy of larotrectinib (LOXO-101) in adult and pediatric TRK fusion cancers at the 2017 ASCO Annual Meeting in Chicago, IL.

LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
Shared By : AnnualMeeting2017
Posted on : 06/06/17
Added : 11 months ago
Category : Other